<DOC>
	<DOCNO>NCT01656135</DOCNO>
	<brief_summary>To investigate progression immunological response living-donor kidney transplant recipient treat standard immunosuppressive regimen . Clinical , immunological , health-economic data collect Reference Group Trial use corroborate historical renal transplantation statistic generate reference range future clinical study test immunoregulatory cell therapy adjunct immunosuppressive treatment renal transplantation .</brief_summary>
	<brief_title>Reference Group Trial The ONE Study</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Organ Donor : A prospective donor eligible research follow inclusion criterion apply : 1 . Eligible live kidney donation 2 . Aged least 18 year 3 . An ABO blood type compatible organ recipient 4 . Willing able provide blood sample The ONE Study Subprojects 5 . Willing provide personal medical/biological data trial 6 . Signed date write informed consent . In sign donor information sheet/informed consent form ( DIS/ICF ) , organ donor agree provide blood sample IM Subproject , permit access medical record collection specify demographic medical/biological data trial . Organ Recipient : 1 . Chronic renal insufficiency necessitate kidney transplantation approve receive primary kidney allograft live donor 2 . Aged least 18 year 3 . Able commence immunosuppressive regimen protocolspecified time point 4 . Willing able participate The ONE Study subprojects 5 . Signed date write informed consent . Organ Donor : If prospective donor fulfils follow criterion , ineligible trial : 1 . Genetically identical prospective organ recipient HLA loci 2 . Exposure investigational agent time kidney donation , within 28 day prior kidney donation 3 . Any form substance abuse , psychiatric disorder , condition , opinion Investigator , may invalidate communication Investigator and/or designate study personnel 4 . Subjects unable freely give inform consent ( e.g . individual legal guardianship ) . Organ Recipient : 1 . Patient previously receive , schedule receive , tissue organ transplant plan kidney graft 2 . Known sensitivity tacrolimus , mycophenolate , corticosteroid 3 . Genetically identical prospective organ donor HLA loci 4 . PRA grade &gt; 40 % within 6 month prior enrolment 5 . Previous treatment desensitisation procedure ( without IVIg ) 6 . Concomitant malignancy history malignancy within 5 year prior plan study entry ( exclude successfullytreated nonmetastatic basal/squamous cell carcinoma skin ) 7 . Evidence significant local systemic infection 8 . HIVpositive , EBVnegative suffer chronic viral hepatitis 9 . Significant liver disease , define persistently elevate AST and/or ALT level &gt; 2 x ULN ( Upper Limit Normal range ) 10 . Malignant premalignant haematological condition 11 . Any uncontrolled medical condition concurrent disease could interfere study objective 12 . Any condition , judgement Investigator , would place subject undue risk 13 . Ongoing treatment systemic immunosuppressive drug study entry 14 . Participation another clinical trial study within 28 day prior plan study entry 15 . Female patient childbearing potential positive pregnancy test enrolment 16 . Female patient breastfeed 17 . All female patient childbearing potential UNLESS : 1 . The patient willing maintain highly effective method birth control duration study 2 . The career , lifestyle , sexual orientation patient ensure risk pregnancy duration study ( discretion local Investigator ) 18 . Psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup visit schedule 19 . Any form substance abuse , psychiatric disorder , condition , opinion Investigator , may invalidate communication Investigator and/or designate study personnel 20 . Patients unable freely give inform consent ( e.g . individual legal guardianship ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>gold standard treatment</keyword>
	<keyword>immune monitoring</keyword>
	<keyword>acute rejection</keyword>
	<keyword>graft rejection</keyword>
	<keyword>living-donor</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>kidney transplantation</keyword>
</DOC>